Table S1.
Reagents used: Oligonucleotides
Name | DNA sequence | Melting point |
B | 5′-NH3-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA-3′ | 57.4 |
B′ | 5′-NH3-AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC-3′ | 55.9 |
C | 5′-NH3-AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA-3′ | 57.6 |
C′ | 5′-NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC-3′ | 56.2 |
D | 5′-NH3-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA-3′ | 56.5 |
D′ | 5′-NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT-3′ | 55.7 |
E | 5′-NH3-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA-3′ | 55.7 |
E′ | 5′-NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT-3′ | 54.7 |
F | 5′-NH3-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA-3′ | 56.9 |
F′ | 5′-NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT-3′ | 56.1 |
M | 5′-NH3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3′ | 57.6 |
M′ | 5′-Cy3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3′ | 56.9 |
The table provides the sequences of the oligonucleotides used in the protein immunoassays. All oligonucleotides were synthesized by Integrated DNA Technology and purified via HPLC. The DNA-coding oligomers were pretested for orthogonality to ensure that cross-hybridization between noncomplementary oligomer strands was negligible (<1% in photon counts).